177 Lu-DOTATATE treatment in neuroendocrine tumors. A preliminary study

Belló, Pilar; Falgas, M.; Olmo, M. I. Del; Torres, I.M.; Olivas, C.; Vera, V.; Oliván, P.; Yepes, Andres

doi:10.1016/j.remnie.2017.01.008

Cited by 4 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…177 Lu-DOTATATE as a PRRT agent may induce long-term toxicity to the bone marrow, but a study performed on 274 GEP-NET patients confirms that 177 Lu-DOTATATE therapy has no risk factors for developing persistent hematological dysfunction in GEP-NET patients . Furthermore, two independent studies confirm that 177 Lu-DOTATATE therapy increases the quality of life of GEP-NET patients. , Hervas et al performed a summary of experience with 177 Lu-DOTATATE. They evaluated the biochemical response, imaging methods, toxicity, and quality of life of treatment for 7 patients with metastatic NET.…”

Section: New Reports Of Radiolabeled Amino Acid Based Molecules Used ...mentioning

confidence: 73%

“…43 Furthermore, two independent studies confirm that 177 Lu-DOTATATE therapy increases the quality of life of GEP-NET patients. 44,45 Lu-DOTATATE. 45 Ashley et al reported a case in which they applied a 177 Lu-DOTATATE neoadjuvant therapy before multivisceral transplantation in patients with metastatic small intestinal neuroendocrine neoplasm.…”

Section: ■ Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Radiolabeled Peptides and Antibodies in Medicine

et al. 2020

View full text Add to dashboard Cite

Radiolabeled peptides are a relatively new, very specific radiotracer group, which is still expanding. This group is very diverse in terms of peptide size. It contains very small structures containing several amino acids and whole antibodies. Moreover, radiolabeled peptides are diverse in terms of the binding aim and therapeutic or diagnostic applications. The majority of this class of radiotracers is utilized in oncology, where the same structure can be used in therapy and diagnostic imaging by varying the radionuclide. In this study, we collected new reports of radiolabeled peptide applications in diagnosis and therapy in oncology and other fields of medicine. Radiolabeled peptides are also increasingly being used in rheumatology, cardiac imaging, or neurology. The studies collected in this review concern new therapeutic and diagnostic procedures in humans and new structures tested on animals. We also performed an analysis of clinical trials, which concerns application of radiolabeled peptides and antibodies that were reported in the clinicaltrials.gov database between 2008 and 2018.

show abstract

Section: New Reports Of Radiolabeled Amino Acid Based Molecules Used ...mentioning

confidence: 73%

Section: ■ Introductionmentioning

confidence: 99%

Radiolabeled Peptides and Antibodies in Medicine

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Our finding of few and mild adverse effects are consistent with reported findings. [7][8][9] During serial serological monitoring after therapy, in 10 treatment cycles only 1 (10%) instance of transient grade 1 marrow toxicity was encountered. Öberg 8 and Seregni et al 10 reported transient lowgrade marrow toxicity in 20% and 23% of patients, respectively.…”

Section: Discussionmentioning

confidence: 99%

Lutetium-177 DOTATATE Therapy for Neuroendocrine Tumours: Report of Two Cases

Hui

Kung

Yong

2020

Hong Kong Journal of Radiology

View full text Add to dashboard Cite

“…Los péptidos análogos de la somatostina disponibles actualmente para tratamiento son octeotrida, lanreotida y pasireotida; empleados incluso ligados a radionúclidos, con resultados prometedores. En una neoplasia rara, tan heterogénea y con supervivencia cada vez mayor aún en estadios avanzados, la colaboración multinstitucional con una base de datos común sería fundamental 1,15,17 .…”

Section: Discussionunclassified